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Abstract Meconium ileus at birth, distal intestinal obstruc-
tion syndrome (DIOS), and constipation are an interrelated
group of intestinal obstruction syndromes with a variable
severity of obstruction that occurs in cystic fibrosis patients.
Long-term follow-up studies show that today meconium
ileus is not a risk factor for impaired nutritional status,
pulmonary function, or survival. DIOS and constipation are
frequently seen in cystic fibrosis patients, especially later in
life; genetic, dietary, and other associations have been
explored. Diagnosis of DIOS is based on suggestive
symptoms, with a right lower quadrant mass confirmed on
abdominal radiography, whereas symptoms of constipation
are milder and of longer standing. In DIOS, early
aggressive laxative treatment with oral laxatives (polyeth-
ylene glycol) or intestinal lavage with balanced osmotic
electrolyte solution and rehydration is required, which now
makes the need for surgical interventions rare. Constipation
can generally be well controlled with polyethylene glycol
maintenance treatment.
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Introduction
The survival of cystic fibrosis (CF) patients has dramati-
cally improved because of centralized management of
patients in specialized CF centers, more aggressive use of
antibiotics, and intensive nutritional support [1]. Cystic
fibrosis is mainly characterized by exocrine pancreatic
insufficiency and progressive pulmonary disease, but with
the improved life expectancy, less frequent and less severe
manifestations of CF, such as the intestinal obstruction
syndromes, are becoming clinically more relevant.
Meconium ileus (MI) at birth, distal intestinal obstruction
syndrome (DIOS, formerly designated “meconium ileus
equivalent”), and constipation are all consequences of the
increased viscosity of intestinal mucus and the prolonged
intestinal transit time in CF [2–5]. Meconium ileus is unique
to CF and is characterized by complete intestinal obstruction
in the neonatal period caused by accumulation of inspissated
meconium. After the neonatal period, DIOS emerges,
characterized by complete or incomplete intestinal obstruc-
tion of viscid fecal accumulation in the terminal ileum and
proximal colon. Characteristically, DIOS patients have
abdominal pain, distension, and vomiting in combination
with a right lower quadrant mass, which is palpable and
usually seen on plain abdominal radiography. An important
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DOI 10.1007/s11894-011-0185-9differential diagnosis of DIOS is constipation. However, in
contrast to DIOS, symptoms are usually milder and of longer
standing. Each condition is frequently seen in CF patients,
with constipation in particular being greatly underdiagnosed
in CF [6￿]. This review describes the incidence, genetics, risk
factors, diagnosis, and treatment of MI, DIOS, and consti-
pation in CF.
Incidence and Prevalence
Meconium Ileus Occurs at Birth in 13% to 17% of All CF
Patients [7–10]
Studies on the incidence and prevalence of DIOS and
constipation are difficult to compare because of the different
definitions used. The recent consensus guidelines issued by
the European Society for Pediatric Gastroenterology, Hep-
atology, and Nutrition (ESPGHAN) CF Working Group
define DIOS as an acute, complete or incomplete, fecal
obstruction in the ileocecum, whereas constipation is defined
as gradual fecal impaction of the total colon (Tables 1 and 2)
[10]. Using these definitions, both the incidence (2.2–6.2
episodes per 1000 patient-years) and lifetime prevalence (7–
8%) of DIOS in childhood is low [9, 11￿, 12, 13]. Two
studies report that DIOS incidence and lifetime prevalence
increase as patients become older [12, 13]; indeed, incidence
(23.3 episodes per 1000 patient-years) and lifetime preva-
lence (14–16%) are higher in adult patients [12–14].
Additionally, DIOS is recurrent medical issue, because 20%
of all pediatric patients experienced more than one episode
during a 5-year observation period [11￿].
Reports on lifetime prevalence of constipation are scarce;
only two studies for pediatric patients (published in 1986 and
2010) [9, 13] and one for adult patients (published in 1986)
[13] are available. They show that constipation is very
common in both pediatric (lifetime prevalence 26–47%) and
adult (lifetime prevalence 42%) CF patients [9, 13]. In the
pediatric population, the prevalence of constipation seems to
have increased over time [9, 13]. However, this might be a
false image, because the use of laxatives was a key
component in establishing constipation in both reports, and
laxatives probably are prescribed more readily now in CF
patients suspected of constipation, especially because current
laxatives are almost devoid of side effects [15].
Genetics
Meconium Ileus
Meconium ileus occurs in 13–17% of all CF patients at
birth [7–10], and is clearly influenced by genetic factors,
because a large twin study reports that monozygous twins
show a greater concordance for MI than dizygous twins
[10]. This variation can be partially explained by the cystic
fibrosis transmembrane regulator (CFTR) genotype. For
example, homozygosity for the delta F508 deletion, the
most common CFTR mutation in CF patients, is strongly
associated with the presence of MI [10]. However non-
CFTR genes (ie, modifier genes) also influence the risk for
developing MI [10, 16, 17]. Several genes and regions have
been reported to be associated with MI [9, 10, 16–18], but a
solid association between a causal modifier gene and MI
has yet to be discovered. Rozmahel et al. [18] were the first
to report a modifier locus for MI (Cfm1) on chromosome 7
in a murine CF model. Subsequently, several markers on
human chromosome 19, the region syntenic to the mouse
locus, showed significant linkage with the presence of MI
in 185 CF sibling pairs [16]. However, in a genome-wide
analysis in more than 1000 patients, this reported linkage
between CFM1 and MI could not be replicated [10]. Thus,
a role of CFM1 in the development of MI seems to be
unlikely. The genome-wide analysis by Dorfman et al. [17]
provided two new candidate modifier genes (ADIPOR2 and
SLC4A4), although the function of these genes and their
relation to MI are unknown. In addition, we recently
reported an association between a variant in the CLCA1
gene and MI in European CF patients [9]. The CLCA1 gene
and its ortholog in mice, Clca3, encode a calcium-activated
chloride channel. Recent studies show an important role for
CLCA1/Clca3 in intestinal obstruction in CF; the expres-
sion of Clca3 in the intestine of CF mice, which all die of
intestinal obstruction, is decreased [19, 20], and up-
regulation of Clca3 in CF mice results in ameliorated
intestinal disease and improved survival [20].
Table 1 European society for pediatric gastroenterology, hepatology, and nutrition CF working group definition for distal intestinal obstruction
syndrome (DIOS) in cystic fibrosis
1 Complete intestinal obstruction as evidenced by vomiting of bilious material and/or fluid levels in small intestine on abdominal radiography
2 Fecal mass in ileocecum
3 Abdominal pain and/or distension
Complete DIOS: 1, 2, and 3
Incomplete/impending DIOS: 2 and 3, without 1
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Some studies report an increased frequency of severe CFTR
genotypes in DIOS [14, 11￿], whereas others report no
differences [10], and a large twin study shows equally low
concordance rates for DIOS in monozygous and dizygous
twins [10]. Constipation in CF is not associated with a
severe CFTR genotype [6￿]. Therefore, genetic factors, both
CFTR and non-CFTR, seem not to play an important role in
DIOS or constipation in CF.
Risk Factors
Relationship with Diet
The relationship between pancreatic insufficiency, or poorly
controlled steatorrhea, and constipation or DIOS is unclear;
conflictingresultshavebeenpublished.Ingeneral,it isthought
that constipation correlates with high doses of pancreatic
supplements [21, 22]. However, this is not supported by
Baker et al. [23], who report no correlation between
constipation and the dosage of pancreatic supplements. We
recently found that constipated patients had a lower total fat
absorption than control patients, although both patient groups
(with and without constipation) had adequate control of
steatorrhea, with a mean total fat absorption of 86% and 90%,
respectively [6￿]. Koletzko et al. [24] also describe a higher
fat excretion in DIOS patients compared to controls. Slow
intestinal transit, as is frequently seen in CF [2, 3], could be
aggravated by a high percentage of undigested food and may
promote the accumulation of fecal material.
Furthermore, fiber and fluid intake are not correlated
with constipation in CF [6￿, 25], despite the general opinion
that inadequate fluid and fiber intake is an etiological factor
of constipation in CF [13].
Relationship with Other Gastrointestinal CF Manifestations
The relationship between MI and CF-related liver disease is
unclear; some report a higher frequency of MI in patients
with CF-related liver disease [26–28], but others report no
differences [29–32, 33￿]. One study even reports a
significantly lower frequency of MI in patients with CF-
related liver disease [34].
A relatively new research topic in CF is intestinal
inflammation. In the majority of the general CF population,
intestinal inflammation is present, as evidenced directly by
capsule endoscopy or indirectly by elevated fecal calprotectin
levels[35, 36]. More specifically, ileal biopsies from both MI
and DIOS patients also show signs of intestinal inflamma-
tion, especially in the myenteric ganglion cells and myocytes
[37￿]. This intestinal inflammation may play a role in the
development of intestinal obstruction in CF, either directly or
indirectly, through delaying intestinal transit time.
We found a surprisingly high frequency of MI in patients
with gastroesophageal reflux disease (42%) compared to
controls (10%) [38]. Our findings are supported by a study
reporting a higher number of reflux episodes in MI patients
[39]. Furthermore, gastrointestinal motility disorders are
frequently reported in CF. For example, CF patients with
symptoms suggesting gastroesophageal reflux may have
esophageal motility defects [40], and in the general CF
population, prolonged intestinal transit time is described [2,
3]. Although the intestinal transit time in MI patients is
unknown, the association between gastroesophageal reflux
disease and MI suggests common defects in gastrointestinal
motility.
After lung transplantation, DIOS is frequently seen; about
10% to 20% of CF lung transplant patients develop at least
oneDIOSepisodeearlyinthepost-transplantperiod[41]. The
transplantation period is characterized by dehydration,
immobility, and opiate use, and in combination with
predisposing factors (eg, MI or abdominal surgery), could
promote fecal impaction in the ileocecum, eventually leading
to complete intestinal obstruction in selected patients. As in
the general CF population [10], DIOS occurs mainly in
patients with a history of MI or laparotomy [41]. Therefore,
starting preventive laxative treatment in these high-risk
patients after lung transplantation could be considered.
Diagnostic Investigations
Constipation is a clinical diagnosis based on a careful history
and physical examination. The recent definition of constipa-
tion includes 1) abdominal pain and/or distension, or 2a) a
reduced frequency of bowel movements in the past few
weeks, and/or 2b) increased consistency of stools in the past
few weeks, while 3) the symptoms are relieved by the use of
laxatives [11￿]. Additionally, complete DIOS is defined as
the combination of 1) complete intestinal obstruction, as
evidenced by vomiting of bilious material and/or fluid levels
in the small intestine on an abdominal radiography, with 2) a
fecal mass in the ileocecum, and 3) abdominal pain and/or
Table 2 European society for pediatric gastroenterology, hepatology,
and nutrition CF working group definition for constipation in cystic
fibrosis
1 Abdominal pain and/or distension
2a Reduced frequency of bowel movements in the past few weeks
or months
2b Increased consistency of stools in the past few weeks or months
3 Symptoms 1 and 2 are relieved by the use of laxatives
Constipation: 1 or 2a or 2b and 3
Curr Gastroenterol Rep (2011) 13:265–270 267distension. Incomplete or impending DIOS is defined as a
short history (days) of abdominal pain and/or distension and
a fecal mass in the ileocecum, but without signs of complete
intestinal obstruction [11￿]. Despite these strict definitions,
diagnosing constipation or DIOS can be a real challenge.
Abdominal radiography in CF patients, using the Barr and
Leech scoring systems, has both a poor value for diagnosing
constipation and poor inter- and intraobserver variability [6￿].
Consequently, abdominal radiography is not recommended
as a standard diagnostic tool in the regular gastrointestinal
follow-up of CF patients. However, abdominal radiography
is useful to differentiate between constipation and DIOS in
CF patients with acute abdominal pain, because DIOS
patients have a fecal mass in the ileocecum with or without
fluid levels in the small intestine, whereas constipation
patients have a distribution of fecal material throughout the
colon [11￿]. Therefore, plain abdominal radiography is
recommended in CF patients with acute abdominal pain.
Treatment and Long-Term Effects
Meconium Ileus
Survival in patients with MI has improved dramatically;
Kerem et al. [7] report that survival through the first year
of life increased from 55% in CF patients born between
1958 and 1972 to 96% in those born between 1973 and
1987. More recent articles even report no differences in
survival between MI and non-MI patients [33￿, 42￿].
Nutritional status follows the same trend as survival; an
older study showed worse long-term nutritional outcomes
in MI patients [7], but more recent reports show no
differences between MI and non-MI patients [33￿, 42￿,
43–45]. In contrast, the long-term outcome of pulmonary
function in MI patients is less uniform between the MI and
non-MI groups. Although the majority of papers report no
differences between patients with or without MI [8, 33￿,
42￿, 43], two other studies report a worse pulmonary
function in MI patients. These ambiguities could be
explained by the control groups used; the first studies
used controls who were diagnosed based on suggestive
symptoms of CF [8, 33￿, 42￿, 43], whereas the last two
studies used matched controls diagnosed in infancy
through a newborn screening program [45, 46]. Conse-
quently, this suggests that MI patients have a worse
pulmonary phenotype, when corrections for the advantage
of early detection and treatment were made.
DIOS and Constipation
Most DIOS episodes can be treated conservatively with
intensive laxative treatment (oral laxatives and/or enema or
polyethylene glycollavage),and mostlargestudies reportlow
numbers of surgical interventions [11￿, 13, 14]. Nevertheless,
the frequency of surgery varies widely among studies (0–
11%) [11￿, 12–14, 41].
For treatment of constipation, we prefer polyethylene
glycol, because it is more effective and does not have the
adverse events inherent to lactulose (flatulence and
abdominal cramps) [15]. For DIOS patients, treatment is
still largely empiric because there are no reported trials. It
is generally recommended to start with an oral laxative
(polyethylene glycol), with or without an enema, and
restoration of adequate hydration, in patients with impend-
ing DIOS and in those with complete DIOS, at least in
patients who do not vomit [47]. When this treatment is not
effective, or in more severe DIOS episodes, intestinal
polyethylene glycol lavage with a balanced electrolyte
osmotic solution is started orally or via nasogastric tube.
In rare cases, the retrograde use of meglumine diatrizoate
(Gastrografin; Schering AG, Berlin, Germany) can be
considered, although this intervention might have serious
complications, such as fluid shift from the circulation to
the bowel leading to shock, perforation, and necrotizing
enterocolitis [47]. Surgery should be used if conservative
treatment is not successful; however, with early aggressive
medical management, surgery is seldom required.
Because most DIOS patients have more than one
episode, continuation of the laxative treatment (polyeth-
ylene glycol) after the first DIOS episode can be
considered and seems logical, although no published
evidence for this approach is available. Furthermore,
dehydration and fat malabsorption (coefficient of fat
absorption < 85%) should be avoided to prevent
recurrence. Finally, in transplantation patients, pre-
transplant bowel preparation with polyethylene glycol
and early postoperative start of enteral feeding seem
appropriate, as does adequate use of pancreatic enzymes
and polyethylene glycol [41].
Conclusions
Intestinal obstruction syndromes are significant issues for
CF patients. Long-term outcomes for MI have improved
dramatically, and today no differences are seen between
MI and non-MI patients. Later in life, DIOS becomes an
issue, with a lifetime prevalence of 8% in pediatric CF
patients and 16% in adult CF patients. In DIOS, early
aggressive laxative treatment with oral laxatives (poly-
ethylene glycol) or intestinal lavage with balanced
osmotic electrolyte solution is almost always effective,
making surgical interventions rare. With adequate use of
polyethylene glycol, constipation, which is frequently
seen in CF, can generally be well controlled.
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